Budesonide/Formoterol Dosing for Asthma and COPD

Asthma Dosing by Age and Severity

For patients with mild-to-moderate persistent asthma, the American College of Cardiology recommends budesonide/formoterol 160/4.5 mcg (2 inhalations twice daily, total 320/9 mcg daily) 1
For patients with moderate-to-severe persistent asthma, budesonide/formoterol 320/4.5 mcg (2 inhalations twice daily, total 640/9 mcg daily) is recommended 1
The preferred Step 3 therapy for mild-to-moderate persistent asthma is low-dose ICS combined with LABA, such as budesonide/formoterol 80/4.5 mcg × 2 inhalations twice daily (total 160/9 mcg daily) 1
For pediatric patients (5-11 years), the age-specific ICS dose ranges are: low dose (0.5 mg total daily), medium dose (1.0 mg total daily), and high dose (2.0 mg total daily) 2
For young children (<4 years), budesonide inhalation suspension (nebulized) is recommended at low dose (0.25-0.5 mg total daily), medium dose (0.5-1.0 mg total daily), and high dose (>1.0-2.0 mg total daily) 2

For patients with moderate-to-severe COPD and frequent exacerbations, triple therapy (LAMA/LABA/ICS) with budesonide 320 mcg reduces mortality compared to LABA/LAMA dual therapy 3

LABA must always be combined with an inhaled corticosteroid to prevent increased exacerbations and treatment failures 1

Rinse mouth after each use to prevent oral candidiasis and dysphonia 1
Use a spacer or valved holding chamber to optimize drug delivery and reduce local side effects 1
For young children, use a face mask that fits snugly over nose and mouth 2

Assess control every 2-6 weeks initially, checking adherence and inhaler technique before adjusting doses 1
Verify proper inhaler technique before concluding therapy is inadequate 1
If well-controlled for ≥3 consecutive months, consider stepping down to lower dose or discontinuing LABA 1
Increasing rescue SABA use (>2 days/week, excluding exercise prevention) indicates inadequate control and need for step-up therapy 1

Begin with the lowest dose appropriate for severity and titrate up only if needed 1
Ensure patients remain on optimized ICS dose for 2-6 weeks with proper adherence before stepping down 1
Never discontinue budesonide therapy abruptly, as this may lead to asthma exacerbation 2
Monitor for cough, dysphonia, and oral thrush, particularly at higher doses 1
At low-to-medium doses, transient growth velocity suppression may occur in children 2

The European Respiratory Society-supported FACET study found that budesonide 800 mcg daily combined with formoterol 24 mcg daily reduced exacerbations by 40% for mild exacerbations and 29% for severe exacerbations compared to budesonide alone in patients with moderate-to-severe persistent asthma 4, 5, 6
The American Academy of Allergy, Asthma, and Immunology recommends that long-acting beta-agonists, such as formoterol, must always be combined with an inhaled corticosteroid, like budesonide, to prevent increased exacerbations and treatment failures 7

The Global Initiative for Asthma guidelines suggest that adding a long-acting beta-agonist to a low-dose inhaled corticosteroid can be more effective than doubling the inhaled corticosteroid dose, as demonstrated by the FACET study 4, 5